b
r
c
nucleo
ide
analogu
play
pivot
role
antivir
cytotox
immunosuppress
agent
review
recent
report
nucleosid
analogu
exhibit
broadspectrum
activ
toward
multipl
lifethreaten
rna
dna
virus
also
present
discuss
nucleosid
antimetabolitesapprov
antineoplast
agentsthat
recent
shown
antivir
andor
antibacteri
activ
approv
drug
drug
combin
well
recent
identifi
candid
investig
andor
experiment
discuss
sever
exampl
repurpos
drug
alreadi
approv
use
present
strategi
crucial
firstlin
treatment
acut
infect
coinfect
manag
drugresist
strain
epidem
pandem
signific
impact
human
histori
centuri
recent
world
health
organ
issu
report
new
viral
pathogen
pose
threat
public
health
almost
everi
year
emerg
epidem
caus
new
pathogen
strain
pathogen
preced
viral
pathogen
necessit
develop
effect
strategi
combat
prevent
viral
infect
immunoprophylaxi
specif
vaccin
one
import
strategi
combat
mani
infecti
diseas
howev
still
mani
virus
effect
vaccin
avail
market
case
use
effect
antivir
drug
possibl
way
fight
infect
caus
virus
introduct
new
antivir
agent
clinic
use
revolution
treatment
mani
viral
infect
caus
either
dna
rna
virus
de
clercq
li
de
clercq
chaudhuri
et
al
approv
drug
licens
treatment
infect
caus
singl
viru
howev
drug
antivir
activ
sever
virus
also
discov
suggest
univers
mechan
action
drug
belong
group
broadspectrum
antivir
particular
interest
sinc
pleiotrop
effect
may
show
activ
virus
undefin
thu
far
ianevski
et
al
recent
sever
approv
antivir
anticanc
drug
nucleo
ide
antimetabolit
group
report
show
newli
discov
antiviralantibacteri
activ
jordheim
et
al
thomson
lamont
nucleo
ide
analogu
much
structur
divers
natur
occur
counterpart
seleyradtk
yate
yate
seleyradtk
modif
may
introduc
nucleobas
sugar
moieti
phosphat
residu
nucleobas
may
modifi
halogen
azot
nconjug
ring
open
introduct
anoth
heterocycl
system
sugar
moieti
substitu
exchang
remov
configur
carbon
atom
ring
chang
addit
heteroatom
introduc
ring
oxygen
ring
replac
anoth
atom
moreov
ring
size
chang
replac
acycl
fragment
phosphat
fragment
may
protect
replac
anoth
phosphoruscontain
group
fragment
deriv
anoth
compound
eg
amino
acid
complet
elimin
review
summar
current
avail
nucleo
idebas
drug
acycl
analogu
exhibit
multitarget
activ
compet
natur
nucleotid
substrat
incorpor
elong
viral
dna
chain
lack
group
incorpor
nucleo
ide
analogu
prevent
format
phosphodiest
linkag
essenti
continu
dna
chain
elong
therefor
viral
dna
growth
termin
lamivudin
analogu
lcytidin
sulphur
atom
replac
carbon
pentos
ring
tenofovir
acycl
analogu
adenosin
market
form
two
prodrug
tenofovir
disoproxil
tdf
viread
tenofovir
alafenamid
taf
vemlidi
role
two
prodrug
treatment
prophylaxi
hiv
hbv
infect
comprehens
compar
de
clercq
de
clercq
tendenc
substitut
tenofovir
disoproxil
tenofovir
alafenamid
antihiv
antihbv
treatment
report
although
drug
pose
littl
risk
viru
drug
resist
telbivudin
lthymidin
use
treatment
hepat
b
infect
clinic
trial
shown
drug
significantli
effect
lamivudin
less
like
caus
resist
moreov
telbivudin
pleiotrop
immunomodulatori
antiinflammatori
properti
rehermann
bertoletti
recent
shown
telbivudin
confer
endothelialprotect
effect
endotheli
cell
improv
chronic
myocard
associ
transcript
activ
van
linthout
et
al
treatment
hbv
infect
usual
carri
monotherapi
thu
combin
therapi
gener
recommend
de
clercq
one
except
use
ribavirin
combin
standard
therapi
enhanc
current
treatment
regimen
ribavirin
commonli
use
treat
hcv
evid
also
induc
immun
effect
posit
affect
hbv
treatment
studi
antihbv
treatment
ribavirin
tenofovir
compar
tenofovir
treatment
alon
current
phase
clinic
trial
contrast
hbv
combin
treatment
standard
treatment
hiv
infect
mani
year
nucleosid
revers
transcriptas
inhibitor
nrti
commonli
administ
drug
highli
activ
antiretrovir
therapi
haart
target
multipl
stage
hiv
life
cycl
lamivudin
tenofovir
among
import
drug
use
combin
da
et
al
accord
survey
among
top
smallmolecul
combin
frequent
util
drug
compon
antihiv
lamivudin
occur
time
tenofovir
disoproxil
occur
time
lamivudin
tenofovir
combin
nrti
eg
abacavir
emtricitabin
zidovudin
nonnucleosid
revers
transcriptas
inhibitor
nnrti
eg
efavirenz
darunavir
rilpivirin
doravirin
inhibitor
hiv
integras
elvitegravir
dolutegravir
raltegravir
bictegravir
also
found
sever
composit
tabl
fig
one
recent
approv
antihiv
combin
biktarvi
bictegravir
emtricitabin
tenofovir
alafenamid
current
phase
clinic
trial
hivhbv
coinfect
primari
object
breast
cancer
shaimerdenova
et
al
ebv
pagano
et
al
azacitidin
cytidin
analogu
myelodysplast
syndrom
adv
alexeeva
et
al
alexeeva
et
al
hmpv
et
al
dapp
et
al
rawson
et
al
synergi
combin
resveratrol
rawson
et
al
beach
et
al
rvfv
ianevski
et
al
diamantopoulo
et
al
fluav
ianevski
et
al
brivudin
thymidin
analogu
clofarabin
adenosin
analogu
acut
lymphoblast
leukaemia
dali
et
al
beach
et
al
decitabin
cytidin
analogu
myelodysplast
syndrom
clouser
et
al
synergi
combin
gemcitabin
clouser
et
al
synergi
combin
resveratrol
jonathan
mo
rawson
et
al
mulv
clouser
et
al
famciclovir
acycl
guanosin
analogu
hsv
vzv
galidesivir
adenosin
analogu
ebov
na
marv
phase
yfv
phase
zikv
juland
et
al
broadspectrum
antivir
westov
et
al
ganciclovir
acycl
guanosin
analogu
hsv
vzv
cmv
ebv
pagano
et
al
gemcitabin
cytidin
analogu
variou
carcinoma
nonsmal
cell
lung
cancer
pancreat
cancer
bladder
cancer
breast
cancer
ovarian
cancer
rawson
et
al
clouser
et
al
clouser
et
al
synergi
combin
decitabin
clouser
et
al
mulv
clouser
et
al
beach
et
al
zikv
kuivanen
et
al
enterovirus
includ
polioviru
kang
et
al
zhang
et
al
enterovirus
synergi
ribavirin
kang
et
al
rhinovirus
song
et
al
hcv
beran
et
al
coronavirus
dyall
et
al
sinv
fluav
denisova
et
al
gramposit
bacteria
jordheim
et
al
sandrini
et
al
thomson
lamont
enterovirus
bauer
et
al
influenza
viru
pauli
laur
continu
next
page
studi
evalu
efficaci
safeti
fixeddos
combin
adult
coinfect
hbv
tabl
present
commonli
use
combin
nrti
nnrti
hiv
integras
inhibitor
fig
show
structur
compound
list
tabl
group
accord
chemic
characterist
molecular
target
last
two
decad
notabl
progress
made
develop
antihcv
drug
treatment
pegyl
interferon
pegifn
ribavirin
hcv
erad
replac
second
gener
directact
antivir
daa
compar
previou
treatment
daa
offer
better
toler
hcv
erad
almost
case
sagnelli
et
al
singl
drug
combin
two
daa
differ
class
market
highli
activ
drug
sofosbuvir
belong
group
nucleotid
prodrug
one
success
exampl
lam
et
al
sofia
et
al
sofosbuvir
approv
fda
use
chronic
hepat
c
infect
sofosbuvir
first
drug
demonstr
safeti
efficaci
treat
certain
type
hcv
infect
without
need
coadministr
inf
high
potenc
sofosbuvir
attribut
part
first
group
built
structur
prodrug
therebi
elimin
first
ratelimit
enzymat
transform
monophosph
addit
group
attach
phosphoru
atom
temporarili
mask
two
neg
charg
phosphat
group
therebi
facilit
entri
drug
infect
cell
murakami
et
al
sofosbuvir
use
either
alon
combin
exampl
present
fig
secondgener
daa
treatment
also
use
hbvhcv
coinfect
patient
sagnelli
et
al
current
drug
combin
ledipasvirsofosbuvir
phase
clinic
trial
use
hbv
infect
observ
patient
hepat
b
hepat
c
treat
hepat
c
week
combin
ledipasvirsofosbuvir
decreas
hepat
b
surfac
antigen
level
find
basi
hypothesi
similar
decreas
could
observ
monoinfect
individu
hepat
b
sofosbuvir
also
recent
shown
protect
zika
flaviviru
zikv
studi
vitro
vivo
mesci
et
al
bullardfeibelman
et
al
found
hcv
zikv
rna
polymeras
similar
activ
site
confirm
sofosbuvir
could
also
act
zikvinfect
cell
also
demonstr
via
cellular
assay
anim
model
sofosbuvir
inhibit
replic
flavivirus
dengu
viru
denv
xu
et
al
yellow
fever
viru
yfv
chikungunya
viru
chikv
even
though
antivir
drug
current
approv
treatment
viral
infect
mani
suitabl
use
singl
viru
de
clercq
li
new
antivir
drug
activ
multipl
viral
type
sought
mani
compound
undergo
advanc
clinic
trial
chaudhuri
et
al
sever
drug
use
diseas
caus
herpesvirus
herpesvirus
classifi
dna
viru
famili
includ
sever
differ
virus
vzv
may
also
call
epsteinbarr
viru
ebv
human
cytomegaloviru
cmv
human
herpesviru
kaposi
sarcomaassoci
herpesviru
kshv
also
known
caus
wide
spectrum
diseas
especi
vertebr
littler
zhou
luczkowiak
et
al
accord
report
approxim
worldwid
popul
younger
year
old
infect
hsv
highli
infecti
viru
caus
socal
cold
sore
mouth
case
infect
genit
case
infect
virus
also
attack
central
nervou
system
caus
enceph
transmit
oral
contact
spread
sexual
contact
looker
et
al
da
hong
vzv
anoth
herpesviru
infect
occur
often
childhood
caus
chickenpox
unfortun
even
cure
patient
viru
remain
latent
bodi
cervic
ganglia
reactiv
host
immun
system
weaken
littler
zhou
drug
use
clinic
treat
herpesviru
infect
divid
two
categori
nucleosid
analogu
nonnucleosid
drug
type
drug
target
viral
dna
polymeras
nucleosidetyp
drug
enter
cell
concentr
nucleosid
transport
canosoldado
pastoranglada
insid
cell
transport
undergo
phosphoryl
nucleosid
kinas
eg
thymidin
kinas
initi
ratelimit
step
lead
monophosph
metabolit
herpesviru
thymidin
kinas
character
broader
substrat
specif
counterpart
mammalian
cell
result
drug
target
herpesvirus
rel
low
toxic
andrei
et
al
second
third
phosphoryl
step
perform
viral
kinas
triphosphoryl
nucleosid
form
way
activ
form
type
drug
bind
activ
site
viral
dna
polymeras
act
competit
inhibitor
enzym
viral
dna
synthesi
activ
form
nucleosidetyp
drug
also
act
substrat
viral
enzym
incorpor
dna
chain
prevent
prolong
viral
dna
possibl
caus
accumul
mutat
multipli
virus
induct
apoptosi
scheme
jordheim
et
al
da
hong
increas
oral
bioavail
antiherpesviru
drug
acyclovir
penciclovir
ganciclovir
amino
acid
esterif
strategi
appli
obtain
compound
valaciclovir
famciclovir
valganciclovir
respect
prodrug
rapidli
convert
activ
form
nucleosidetyp
drug
enzym
liver
intestin
wall
weller
et
al
describ
nucleotidebas
antiherpesviru
drug
activ
one
viru
idoxuridin
idu
fig
iodin
thymidin
analogu
first
antiherpet
drug
discov
w
prusoff
prusoff
licens
fda
treatment
hsv
also
effect
local
therapi
vzv
essmann
wildenhoff
nikkei
howev
signific
toxic
associ
system
use
mechan
action
idoxuridin
exactli
defin
triphosph
inhibit
viral
dna
synthesi
incorpor
viral
cellular
dna
current
unit
state
idoxuridin
approv
topic
treatment
hsv
kerat
europ
idoxuridin
dmso
avail
treatment
herp
labiali
herp
genitali
herp
zoster
aoki
brivudin
bvdu
similar
idoxuridin
thymidin
analogu
approv
drug
use
wide
rang
herpesvirus
brivudin
highli
specif
vzv
howev
show
activ
topali
et
al
drug
wide
avail
europ
except
unit
kingdom
mani
countri
except
unit
state
de
clercq
andrei
et
al
also
found
brivudin
might
use
treat
ebv
enceph
howev
clinic
trial
still
requir
confirm
effect
safe
use
antiebv
drug
lin
et
al
lahmer
et
al
result
comparison
brivudin
famciclovir
valaciclovir
treatment
immunocompet
adult
patient
herp
zoster
indic
brivudin
may
first
choic
case
sever
herp
zoster
abil
promptli
control
pain
onceaday
use
yaldiz
et
al
literatur
also
describ
novel
seri
phosphoramid
nucleosid
idoxuridin
brivudin
prodrug
includ
amino
acid
motif
base
laspart
acid
lglutam
acid
socal
protid
evalu
cytotox
activ
panel
cancer
cell
line
compar
parent
nucleosid
idoxuridin
brivudin
display
weak
moder
activ
correspond
protid
show
increas
cytotox
activ
gao
et
al
trifluridin
trifluorothymidin
tft
belong
group
fluorin
pyrimidin
analogu
compound
use
antihsv
drug
therapi
hsvinduc
epitheli
kerat
convers
trifluridin
monophosph
inhibit
thymidyl
synthetas
elev
differ
cancer
cell
line
phosphoryl
correspond
triphosph
competit
inhibit
dna
polymeras
respect
thymidin
triphosph
aoki
trifluridin
combin
tipiracil
lonsurf
approv
japan
unit
state
european
union
treatment
adult
patient
metastat
colorect
cancer
previous
subject
chemotherapi
involv
fluoropyrimidin
oxaliplatin
irinotecan
bur
duggan
matsuoka
et
al
phase
clinic
trial
also
underway
collect
addit
data
safeti
efficaci
trifluridinetipiracil
treatment
patient
metastat
colorect
cancer
trifluridin
also
test
antibacteri
agent
specif
found
trifluridin
strongli
inhibit
mycoplasma
pneumonia
growth
vitro
sun
wang
unfortun
clinic
trial
undertaken
direct
recent
year
six
approv
acycl
guanosin
analogu
name
acyclovir
ganciclovir
valaciclovir
valganciclovir
penciclovir
famciclovir
fig
first
acyclovir
acv
methyl
guanin
origin
design
inhibitor
adenosin
deaminas
discov
effect
antiherpet
drug
elion
et
al
acyclovir
activ
activ
vzv
also
demonstr
schaeffer
et
al
acyclovir
also
activ
ebv
high
concentr
cmv
activ
base
inhibit
dna
polymeras
caus
dna
chain
termin
activ
acyclovir
form
triphosph
lack
group
requir
dna
chain
elong
laskin
ostroskyzeichn
rex
bioavail
oral
acyclovir
rel
poor
thu
high
dose
drug
requir
also
administ
topic
form
drug
excel
safeti
profil
acyclovir
triphosph
much
better
substrat
viral
polymeras
cellular
polymeras
addit
affin
acyclovir
viral
thymidin
kinas
approxim
greater
cellular
thymidin
kinas
higher
concentr
activ
metabolit
observ
infect
cell
kimberlin
da
hong
studi
conduct
determin
effect
acyclovir
breast
cancer
cell
describ
shaimerdenova
et
al
obtain
result
demonstr
suppress
effect
acyclovir
breast
cancer
cell
acyclovir
treatment
decreas
prolifer
rate
well
growth
cell
correl
upregul
apoptosi
associ
acyclovir
also
inhibit
coloni
format
abil
cell
invas
capac
cancer
cell
result
demonstr
possibl
partial
suppress
cancer
cell
prolifer
use
antivir
agent
howev
research
necessari
determin
mechan
anticanc
activ
acyclovir
literatur
also
describ
approach
base
phosphoryl
acyclovir
viral
thymidin
kinas
cellular
enzym
yao
et
al
phosphoryl
acyclovir
inhibit
cellular
dna
synthesi
kill
infect
cell
assum
phosphoryl
acyclovir
would
cytotox
agent
properli
deliv
cancer
cell
facilit
target
deliveri
phosphoryl
acyclovir
tumour
lipidcalciumphosph
nanoparticl
membranecor
structur
use
encapsul
phosphoryl
drug
nanoparticl
contain
phosphoryl
acyclovir
facilit
deliveri
tumour
contribut
significantli
enhanc
inhibit
tumour
growth
without
obviou
toxic
increas
oral
bioavail
antivir
drug
prodrug
strategi
appli
valaciclovir
vacv
lvalyl
ester
acyclovir
highli
effici
safe
prodrug
acyclovir
dose
oral
absorb
gastrointestin
tract
passiv
transcellular
mechan
activ
peptid
transport
mechan
prodrug
convert
acyclovir
liver
intestin
wall
specif
enzym
weller
et
al
oral
bioavail
valaciclovir
much
higher
acyclovir
reach
almost
clinic
trial
valaciclovir
similar
antivir
activ
safeti
profil
acyclovir
therefor
supersed
acyclovir
treatment
hsv
vzv
infect
obrien
campolirichard
littler
zhou
penciclovir
pcv
butyl
guanin
develop
beecham
pharmaceut
laboratori
acycl
guanosin
analogu
penciclovirtriphosph
activ
metabolit
competit
inhibit
replic
function
viral
dna
polymeras
unlik
acyclovir
penciclovir
consid
dna
chain
termin
due
presenc
group
acycl
part
pcv
allow
dna
chain
elong
incorpor
penciclovir
probabl
distort
dna
conform
induc
suppress
dna
elong
piret
boivin
penciclovir
broadspectrum
antivir
activ
hsv
vzv
even
ebv
less
activ
acyclovir
longer
halflif
higher
intracellular
concentr
compens
lower
antivir
effect
phosphoryl
penciclovir
concentr
much
higher
phosphoryl
acyclovir
littler
zhou
kimberlin
bioavail
penciclovir
upon
oral
administr
poor
approxim
therefor
prodrug
famciclovir
fcv
diacet
design
approv
clinic
use
hsv
vzv
tyre
et
al
luber
flaherti
studi
mous
model
shown
main
advantag
use
famciclovir
use
drug
abil
prevent
latent
infect
thackray
field
ganciclovir
gcv
guanin
differ
acyclovir
extra
hydroxymethyl
group
acycl
chain
due
highli
effici
action
cmv
ganciclovir
approv
use
treatment
infect
viru
belong
socal
betaherpesviru
group
ganciclovir
similar
acyclovir
also
activ
alphaherpesvirus
similar
activ
vzv
kimberlin
ganciclovir
use
success
treat
infect
nakano
et
al
also
proven
effect
vitro
replic
ebv
de
clercq
bioavail
oral
form
less
drug
absorb
oral
administr
jab
et
al
reason
ganciclovir
prodrug
explor
valganciclovir
vgcv
ethoxymethyl
guanin
approv
fda
first
exampl
prodrug
valganciclovir
well
absorb
oral
administr
addit
valyl
ester
group
ganciclovir
make
good
substrat
two
peptid
transport
increas
absorpt
ester
linkag
valyl
group
ganciclovir
easili
hydrolys
intestin
esteras
hepat
esteras
sugawara
et
al
vidarabin
vdr
analogu
adenosin
isol
streptomyc
antibioticu
vidarabin
unlik
previous
discuss
drug
requir
viral
enzym
step
scheme
mechan
action
nucleosidetyp
drug
prodrug
herpesvirus
abbrevi
acv
acyclovir
bvdu
brivudin
iduidoxuridin
fcv
famciclovir
gcv
ganciclovir
pcv
penciclovir
tfttrifluridin
vacv
valaciclovir
vdr
vidarabin
vgcv
valganciclovir
triphosphoryl
process
gener
activ
metabolit
phosphoryl
cellular
enzym
vidarabin
activ
triphosph
form
lack
specif
respons
toxic
vidarabin
oncogen
teratogen
laboratori
anim
model
vidarabin
triphosph
act
competit
inhibitor
viral
cellular
dna
polymeras
function
chain
termin
incorpor
dna
addit
metabolit
also
inhibit
viral
cellular
enzym
ribonucleosid
reductas
sadenosylhomocystein
hydrolas
may
also
contribut
antivir
toxic
effect
vidarabin
aoki
theobald
vidarabin
initi
use
antivir
drug
systemat
treatment
hsv
vzv
infect
de
clercq
vidarabin
use
less
current
past
mainli
use
case
acyclovirresist
herpesvirus
due
rel
insolubl
aqueou
media
vidarabin
mainli
administ
topic
littler
zhou
year
ago
propos
vidarabin
could
appli
potent
select
inhibitor
adenylyl
cyclas
treatment
two
human
diseas
heart
failur
cancer
conclus
base
result
anim
test
iwatsubo
et
al
vatner
et
al
unfortun
follow
year
find
indic
vdr
neither
potent
select
cyclas
inhibitor
publish
seifert
research
develop
signific
number
nucleo
ide
analogu
termin
preclin
assay
stage
due
toxic
induc
anim
model
high
toxic
also
reason
reject
mani
compound
clinic
trial
exampl
nucleo
idebas
analogu
exhibit
high
activ
herpesvirus
approv
drug
shown
fig
describ
valomaciclovir
prodrug
undergon
preliminari
stage
clinic
trial
inhibit
viral
dna
polymeras
ester
nucleosid
analogu
rapidli
convert
omaciclovir
vivo
subsequ
convert
viral
enzym
phosphoryl
form
bind
vzv
polymeras
vitro
studi
shown
activ
vzv
abel
et
al
valomaciclovir
phase
clinic
trial
ebvinfecti
mononucleosi
well
treatment
herp
zoster
cyclopropavir
anoth
extens
investig
compound
methylenecyclopropan
nucleosid
analogu
structur
relat
drug
acyclovir
ganciclovir
penciclovir
vitro
studi
demonstr
activ
herpesvirus
cmv
price
prichard
cyclopropavir
phase
clinic
trial
assess
safeti
pharmacokinet
anoth
compound
exhibit
strong
antivir
activ
compound
high
select
vzv
unfortun
activ
observ
compar
studi
herpesvirus
mcguigan
et
al
drug
test
phase
clinic
trial
comparison
valaciclovir
herp
zoster
phase
clinic
trial
comparison
valaciclovir
prevent
postherpet
neuralgia
brincidofovir
lipid
conjug
cidofovir
seem
promis
antivir
compound
contrast
latter
brincidofovir
oral
avail
absorb
small
intestin
transport
throughout
bodi
phospholipid
cross
target
cell
membran
facilit
passiv
diffus
addit
long
intracellular
halflif
brincidofovir
present
broadspectrum
antivir
activ
dna
virus
herpesvirus
adenovirus
poxvirus
price
prichard
florescu
et
al
quenel
et
al
studi
safeti
efficaci
adenoviru
adv
infect
phase
clinic
trial
seriou
diseas
condit
caus
dna
virus
phase
anoth
clinic
trial
phase
reveal
patient
take
brincidofovir
resist
cmv
infect
unfortun
result
phase
trial
show
effect
observ
activ
drug
administr
disappear
immedi
treatment
moreov
signific
number
patient
develop
diarrhoea
result
two
clinic
trial
cmv
prevent
stop
nucleosid
antimetabolit
use
broad
rang
human
cancer
includ
leukaemia
lymphoma
pancreat
breast
bladder
ovarian
colon
kidney
cancer
mimick
physiolog
role
natur
counterpart
interfer
cellular
metabol
incorpor
dna
rna
inhibit
enzym
essenti
polymeras
dna
methyltransferas
kinas
phosphorylas
thymidyl
synthas
ribonucleotid
reductas
thu
inhibit
cell
divis
viral
replic
jordheim
et
al
among
major
player
purin
analogu
includ
commonli
use
cladribin
approv
fludarabin
approv
secondgener
clofarabin
approv
nelarabin
approv
pyrimidin
analogu
first
approv
cytarabin
gemcitabin
azacytidin
decitabin
floxuridin
import
role
sever
cancer
treatment
parker
cytotox
nucleosid
analogu
recent
proven
broadspectrum
antivir
activ
toward
lifethreaten
virus
ianevski
et
al
among
cytidin
analogu
gemcitabin
report
list
broadspectrum
antivir
show
vitro
activ
addit
recent
report
sever
nucleosid
analogu
clinic
approv
antivir
antineoplast
agent
also
show
antibacteri
activ
thomson
lamont
exampl
drug
includ
gemcitabin
zidovudin
floxuridin
idoxuridin
thiopurin
applic
limit
nucleosid
analogu
antibiot
could
connect
side
effect
toxic
eg
myelosuppress
pulmonari
toxic
howev
concentr
nucleosid
analogu
inhibit
growth
bacteria
lower
use
treatment
cancer
patient
reduc
problem
toxic
jordheim
et
al
antibiot
potenc
nucleosid
analogu
could
use
especi
hospit
set
treat
multidrugresist
bacteria
chapter
approv
antineoplast
drug
nucleosid
antimetabolit
group
shown
potenc
broadspectrum
antivir
agent
andor
antibacteri
agent
discuss
fig
gemcitabin
dfdc
dfdcyd
approv
antineoplast
drug
initi
approv
fda
brand
name
gemzar
use
treatment
differ
cancer
eg
pancreat
ovarian
lung
breast
bladder
cancer
hertel
et
al
cerqueira
et
al
prodrug
convert
monophosph
metabolit
deoxycytidin
kinas
activ
diphosph
triphosph
metabolit
nucleosid
monoand
diphosph
kinas
respect
diphosph
metabolit
act
inhibitor
ribonucleotid
reductas
catalyst
deoxyribonucleotid
gener
dna
synthesi
repair
triphosph
metabolit
turn
compet
natur
incorpor
replic
dna
cerqueira
et
al
gemzar
combin
cisplatin
approv
treatment
local
advanc
metastat
nonsmal
cell
lung
cancer
gemzar
combin
paclitaxel
approv
firstlin
therapi
women
battl
metastat
breast
cancer
gemzar
demonstr
dosedepend
synergist
activ
cisplatin
treatment
advanc
ovarian
cancer
least
month
complet
platinumbas
therapi
gemcitabin
use
combin
carboplatin
anoth
studi
show
cotreat
gemcitabin
zidovudin
resensit
gemcitabineresist
pancreat
cancer
inhibit
key
signal
pathway
resist
cell
namba
et
al
report
phase
clinic
trial
shown
combin
brivudin
gemcitabin
cisplatin
enhanc
efficaci
pancreat
cancer
therapi
heinrich
et
al
recent
fda
approv
premix
readytoinfus
formul
call
infugem
sever
gener
version
gemzar
also
approv
recent
experiment
data
antivir
activ
gemcitabin
wide
report
shin
et
al
ianevski
et
al
broad
rang
virus
gemcitabin
shown
activ
includ
rawson
et
al
clouser
et
al
clouser
et
al
murin
leukaemia
viru
mulv
clouser
et
al
beach
et
al
zikv
kuivanen
et
al
enterovirus
polioviru
kang
et
al
zhang
et
al
rhinovirus
song
et
al
hcv
beran
et
al
coronavirus
dyall
et
al
sindbi
viru
sinv
fluav
denisova
et
al
synergist
effect
gemcitabin
combin
low
dose
nucleosid
analogu
also
report
appli
combin
ribavirin
treatment
enterovirus
decitabin
fig
addit
nucleo
idebas
antivir
agent
variou
herpesvirus
g
et
al
european
journal
pharmacolog
treatment
hiv
kang
et
al
clouser
et
al
case
gemcitabin
inhibit
virus
low
noncytotox
concentr
denisova
et
al
kuivanen
et
al
depend
viru
gemcitabin
shown
inhibitor
viral
replic
prolifer
rna
protein
synthesi
product
gemcitabin
antivir
effect
enterovirus
propos
base
two
action
directli
incorpor
newli
synthes
viral
rna
polymer
process
gemcitabin
preferenti
incorpor
viral
rna
sinc
rna
replic
process
virus
activ
cellular
dna
rna
synthesi
also
possibl
gemcitabin
block
rna
polymeras
bind
nucleotidebind
region
anoth
possibl
viral
ribonucleotid
reductas
inhibit
result
increas
mutat
rate
loss
viral
prolifer
capabl
kang
et
al
postul
inhibit
rna
replic
might
relat
limit
amount
nucleosid
avail
song
et
al
cytidin
analogu
gemcitabin
report
inhibit
salvag
pathway
pyrimidin
biosynthesi
addit
treatment
gemcitabin
activ
express
sever
ifnstimul
gene
includ
major
effector
innat
immun
gemcitabin
also
shown
antibacteri
activ
gramposit
bacteria
enterococcu
listeria
bacillu
staphylococcu
includ
multidrugresist
strain
staphylococcu
aureu
thomson
lamont
jordheim
et
al
sandrini
et
al
unfortun
one
studi
reveal
treat
strain
develop
resist
gemcitabin
phenomenon
could
turn
overcom
combin
gemcitabin
gentamicin
show
synergist
activ
reduc
rate
resist
develop
jordheim
et
al
gemcitabin
show
activ
gramneg
bacteria
azacitidin
azacr
vidaza
prodrug
antimetabolit
cytidin
approv
fda
treatment
subtyp
myelodysplast
syndrom
md
date
azacytidin
also
approv
treatment
acut
myeloid
leukaemia
aml
patient
bone
marrow
bm
blast
bm
blast
agraw
et
al
antineoplast
activ
base
two
mechan
action
hypomethyl
dna
direct
toxif
abnorm
haematopoiet
cell
bm
toxic
cell
sphase
cell
cycl
kaminska
et
al
incorpor
dna
azacytosin
substitut
cytosin
form
azacytosineguanin
dinucleotid
recogn
dna
methyltransferas
natur
substrat
inhibit
enzym
stresemann
lyko
agraw
et
al
mechan
result
reduct
dna
methyl
hypomethyl
agentsazacitidin
decitabinewer
report
influenc
tumour
interact
host
immun
system
activ
endogen
retrovir
element
normal
epigenet
silenc
wolff
et
al
experiment
studi
shown
azacitidin
potent
broadspectrum
antivir
agent
rang
virus
show
activ
includ
adv
alexeeva
et
al
alexeeva
et
al
human
metapneumoviru
hmpv
et
al
dapp
et
al
rawson
et
al
beach
et
al
rift
valley
fever
viru
rvfv
ianevski
et
al
human
tlymphotrop
viru
diamantopoulo
et
al
fluav
ianevski
et
al
studi
azacytidin
activ
reveal
primarili
target
revers
transcript
form
triphosph
increas
mutat
rate
caus
incorpor
azacytidin
viral
rna
observ
dapp
et
al
addit
studi
indic
mutagenesi
enhanc
reduct
led
gtoc
hypermut
rawson
et
al
comparison
azacytidin
activ
toward
reveal
better
efficaci
toward
ec
valu
respect
beach
et
al
combin
low
concentr
ribonucleotid
reductas
inhibitor
eg
resveratrol
synergist
effect
significantli
reduc
infect
synerg
explain
reduc
accumul
revers
transcript
product
rather
increas
viral
mutagenesi
rawson
et
al
recent
studi
human
adenovirus
reveal
azacytidin
effect
antivir
agent
wide
rang
concentr
deriv
show
even
better
result
name
n
n
high
select
adv
low
cytotox
observ
alexeeva
et
al
decitabin
dac
dacogen
demylocan
anoth
antineoplast
antimetabolit
cytidin
analogu
hypomethyl
agent
approv
fda
treatment
multipl
type
myelodysplast
syndrom
promot
cytotox
dna
hypomethyl
cell
death
rapidli
divid
cell
disrupt
dna
synthesi
similar
azacytidin
decitabin
also
induc
immun
respons
sensit
tumour
checkpoint
inhibit
wolff
et
al
addit
shown
muscleinvas
bladder
cancer
cell
decitabin
treatment
low
noncytotox
dose
restor
express
promot
releas
induc
differenti
ramakrishnan
et
al
antivir
activ
decitabin
shown
mostli
hiv
fig
structur
nucleosid
antimetabolit
potenti
antivir
activ
g
et
al
european
journal
pharmacolog
treatment
similar
previous
describ
synergist
effect
azacytidin
resveratrol
combin
decitabin
resveratrol
significantli
reduc
level
revers
transcript
product
rawson
et
al
anoth
studi
indic
combin
gemcitabin
decitabin
concentr
much
lower
use
cancer
treatment
synergist
lower
infect
significantli
increas
mutat
frequenc
clouser
et
al
clofarabin
cafda
clfaraa
clolar
evoltra
fda
approv
antineoplast
agent
use
treat
lymphoblast
leukaemia
specif
acut
lymphoblast
leukaemia
paediatr
patient
age
whose
diseas
relaps
becom
refractori
least
two
prior
treatment
regimen
drug
act
antimetabolit
interfer
dna
replic
clofarabin
inhibit
ribonucleotid
reductas
caus
termin
dna
chain
elong
inhibit
dna
polymeras
addit
disrupt
mitochondri
membran
integr
result
releas
apoptosisinduc
factor
proapoptot
protein
cytochrom
c
lead
activ
program
cell
death
pathway
clofarabin
report
potent
antiretrovir
agent
shown
threefold
higher
activ
beach
et
al
studi
activ
clofarabin
reveal
dual
inhibitori
function
viru
replic
limit
deoxyribonucleosid
triphosph
substrat
synthesi
viral
dna
directli
inhibit
dna
polymeras
activ
revers
transcriptas
dali
et
al
nucleosid
analogu
first
studi
antimetabolit
prove
antitumour
agent
mani
antitumour
agent
show
antivir
activ
howev
develop
signific
number
nucleo
idebas
analogu
termin
preclin
assay
stage
due
toxic
induc
anim
model
longterm
exposur
antivir
drug
lead
emerg
drug
resist
addit
case
limit
standard
treatment
result
signific
renal
toxic
effect
therefor
constant
need
develop
novel
therapeut
agent
current
activ
antivir
drug
candid
advanc
preclin
clinic
trial
clinicalstag
drug
candid
test
activ
hiv
hbv
hcv
even
though
antivir
drug
current
approv
treatment
viral
infect
mani
suitabl
use
singl
viru
new
antivir
drug
activ
multipl
viral
type
sought
mani
compound
subject
advanc
clinic
trial
moreov
experiment
data
open
possibl
repurpos
broadspectrum
antimetabolit
viral
infect
drug
alreadi
approv
applic
could
save
time
money
need
prove
safeti
possibl
compound
alreadi
classifi
drug
one
viru
may
suitabl
treatment
viral
infect
approach
particularli
import
candid
treatment
deadli
viral
infect
ebola
viru
ebov
case
safeti
threshold
would
base
differ
criteria
current
appli
drug
use
control
chronic
infect
hiv
hbv
